NF-κB pathway play a role in SCD1 deficiency-induced ceramide de novo synthesis

Rui-He Zheng,Yi-Bo Zhang,Fu-Nan Qiu,Zhao-Hui Liu,Yun Han,Rui Huang,Yun Zhao,Peijie Yao,Yan Qiu,Jie Ren

DOI: https://doi.org/10.1080/15384047.2021.1883414

2021-02-01

Abstract:<span>Stearoyl-CoA-desaturase 1 (SCD1) deficiency mediates apoptosis in colorectal cancer cells by promoting ceramide <i>de novo</i> synthesis. The mechanisms underlying the cross-talk between SCD1 and ceramide synthesis have not been explored. We treated colorectal cancer cells with an SCD1 inhibitor and examined the effects on gene expression, cell growth, and cellular lipid contents. The main effect of SCD1 inhibition on the fatty acid contents of colorectal cancer cells was a decrease in monounsaturated fatty acids (MUFAs). RNA sequencing (RNA-seq) showed that the most intense alteration of gene expression after SCD1 inhibition occurred in the NF-κB signaling pathway. Further experiments revealed that SCD1 inhibition resulted in increased levels of phosphorylated NF-κB p65 and increased nuclear translocation of NF-κB p65. Treatment with an NF-κB inhibitor eliminated several effects of SCD1 inhibition, mainly including overexpression of serine palmitoyltransferase1 (SPT1), elevation of dihydroceramide contents, and suppression of cell growth. Furthermore, treatment with supplemental oleate counteracted the SCD1-induced NF-κB activation and downstream effects. In summary, our data demonstrate that the NF-κB pathway plays a role in SCD1 deficiency-induced ceramide <i>de novo</i> synthesis in colorectal cancer cells, and that reduced MUFA levels contribute to the course.</span>

oncology